scholarly journals How to Perform Umbilical Cord Arterial and Venous Blood Sampling in Neonatal Foals

2019 ◽  
Vol 73 ◽  
pp. 24-29 ◽  
Author(s):  
Sunita S. Jeawon ◽  
Lisa M. Katz ◽  
Noreen P. Galvin ◽  
Stephen D. Cahalan ◽  
Vivienne E. Duggan
Keyword(s):  
Umbilical Cord ◽  
Venous Blood ◽  
Blood Sampling ◽  
Venous Blood Sampling

scholarly journals An Anti-Nucleocapsid Antigen Sars-Cov-2 Total Antibody Assay Finds Comparable Results in Edta-Anticoagulated Whole Blood Obtained from Capillary and Venous Blood Sampling

Data ◽  
2020 ◽  
Vol 5 (4) ◽  
pp. 105
Author(s):  
Martin Risch ◽  
Marc Kovac ◽  
Corina Risch ◽  
Dorothea Hillmann ◽  
Michael Ritzler ◽  
...  
Keyword(s):  
Whole Blood ◽  
Venous Blood ◽  
Capillary Blood ◽  
Blood Sampling ◽  
Attractive Alternative ◽  
Antibody Assay ◽  
Antibody Assays ◽  
Antibody Titers ◽  
Antibody Levels ◽  
Venous Blood Sampling

Although SARS-CoV-2 antibody assays have been found to provide valid results in EDTA-anticoagulated whole blood, so far, they have not demonstrated that antibody levels in whole blood originating from capillary blood samples are comparable to antibody levels measured in blood from a venous origin. Here, blood is drawn simultaneously by capillary and venous blood sampling. Antibody titers are determined by an assay employing electrochemiluminescence (ECLIA) and SARS-CoV-2 total immunoglobulins are detected with specificity directed against the nucleocapsid antigen. Six individuals with confirmed COVID-19 and six individuals without COVID-19 are analyzed. Antibody titers in capillary venous whole blood did not show significant differences, and when corrected for hematocrit, they did not differ from the results obtained from serum. In conclusion, capillary sampled EDTA-anticoagulated whole blood seems to be an attractive alternative matrix for the evaluation of SARS-CoV-2 antibodies when employing ECLIA for detecting total antibodies directed against nucleocapsid antibodies.

scholarly journals Improving the quality of venous blood sampling procedure (phlebotomy): avoiding tourniquet use

2020 ◽  
Author(s):  
Francisco Freitas ◽  
Mónica Alves
Keyword(s):  
Venous Blood ◽  
Real Life ◽  
Sampling Procedure ◽  
T Test ◽  
Blood Sampling ◽  
Age Group ◽  
The Individual ◽  
Sampling Procedures ◽  
Without Tourniquet ◽  
Venous Blood Sampling

AbstractBackgroundGuidelines for venous blood sampling procedure (phlebotomy) discourage tourniquet use whenever possible. Here, we aimed to assess the Biomedical Scientists capability of not using the tourniquet in phlebotomy, which we hypothesized to be equal to 50% of the patients attended, and identifying the most frequent venipuncture site.Materials and MethodsWe selected and assigned two (BMS) with the same age (41 years) and experience (20 years) to record ten phlebotomy days, the first with prioritized and the latter with non-prioritized patients. In a simple record form, each acquired daily data for the number of attended patients, age and gender, the frequency of non-tourniquet usage and the punctured vein. To test our work hypothesis we used the two-tailed single sample t-test (p < 0.05). Differences between age-group means and non-tourniquet use means by each BMS were tested by two-tailed t-test for independent means (p < 0.05).ResultsIn 10 phlebotomy days 683 patients were attended, with males representing 43,2% of the population. We found no statistically difference between age-group means. The combined capability of non-tourniquet use was 50,5%, which did not differ from our null hypothesis, but the individual group-means were statistically different, being 33% and 66.9% in the prioritized vs non-prioritized group. The medial cubital vein was the most prone to be punctured (77,7%).ConclusionsWe have shown that performing phlebotomies without tourniquet use is possible and desirable in at least half of the attended patients, though being more limited in specific group populations. Our results provide room for quality improvement in the laboratory pre-analytical phase.Key points summaryWe assessed the capability of Biomedical Scientists not using the tourniquet in real life blood sampling procedures for diagnostic purposes.Blood was collected from at least half of the attended patients without tourniquet use.Biomedical Scientists were able to prioritize the antecubital veins without tourniquet application (medial cubital vein the most prone to be punctured - 78% of attempts).

scholarly journals Dried Blood Spot Analysis Suitable for Therapeutic Drug Monitoring of Voriconazole, Fluconazole, and Posaconazole

2013 ◽  
Vol 57 (10) ◽  
pp. 4999-5004 ◽  
Author(s):  
Kim C. M. van der Elst ◽  
Lambert F. R. Span ◽  
Kai van Hateren ◽  
Karin M. Vermeulen ◽  
Tjip S. van der Werf ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Sampling Method ◽  
Fungal Infections ◽  
Venous Blood ◽  
Blood Sampling ◽  
Dried Blood Spot ◽  
Therapeutic Drug ◽  
Venous Blood Sampling ◽  
Blood Spot

ABSTRACTInvasive aspergillosis and candidemia are important causes of morbidity and mortality in immunocompromised and critically ill patients. The triazoles voriconazole, fluconazole, and posaconazole are widely used for the treatment and prophylaxis of these fungal infections. Due to the variability of the pharmacokinetics of the triazoles among and within individual patients, therapeutic drug monitoring is important for optimizing the efficacy and safety of antifungal treatment. A dried blood spot (DBS) analysis was developed and was clinically validated for voriconazole, fluconazole, and posaconazole in 28 patients. Furthermore, a questionnaire was administered to evaluate the patients' opinions of the sampling method. The DBS analytical method showed linearity over the concentration range measured for all triazoles. Results for accuracy and precision were within accepted ranges; samples were stable at room temperature for at least 12 days; and different hematocrit values and blood spot volumes had no significant influence. The ratio of the drug concentration in DBS samples to that in plasma was 1.0 for voriconazole and fluconazole and 0.9 for posaconazole. Sixty percent of the patients preferred DBS analysis as a sampling method; 15% preferred venous blood sampling; and 25% had no preferred method. There was significantly less perception of pain with the DBS sampling method (P= 0.021). In conclusion, DBS analysis is a reliable alternative to venous blood sampling and can be used for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole. Patients were satisfied with DBS sampling and had less pain than with venous sampling. Most patients preferred DBS sampling to venous blood sampling.

Sign in / Sign up

Export Citation Format

Share Document